474645-96-0

Basic information

• Product Name: Carbamic acid, [(2R,4S)-2-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-4-quinolinyl]-, phenylmethyl ester
• CAS NO: 474645-96-0
• Molecular Formula: C20H21F3N2O2
• Molecular Weight: 378.394
• Mol File: 474645-96-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(2R,4S)-2-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-4-quinolinyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(2R,4S)-2-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-4-quinolinyl]-, phenylmethyl ester(474645-96-0)
• EPA Substance Registry System: Carbamic acid, [(2R,4S)-2-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-4-quinolinyl]-, phenylmethyl ester(474645-96-0)

Safety Data

• Hazardous Substances Data: 474645-96-0(Hazardous Substances Data)

Upstream product

• 400090-60-0 (R)-3-aminopentanenitrile 
• 455-14-1 4-trifluoromethylphenylamine 
• 84713-20-2 benzyl N-vinylcarbamate 
• 123-38-6 propionaldehyde 
• 98-56-6 4-chlorobenzotrifluoride 
• 667937-05-5 (3R)-3-(4-trifluoromethylphenylamino)pentanoic acid amide 
• 474645-91-5 (R)-3-((4-(trifluoromethyl)phenyl)amino)pentanenitrile 
• 474645-97-1 (R)-3-aminopentanenitrile methanesulfonic acid salt 
• 343798-02-7 (1-benzotriazol-1-yl-propyl)-(4-trifluoromethyl-phenyl)-amine 

Downstream Products

• 1140966-17-1 (2R,4S)-4-benzyloxycarbonylamino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 
• 874501-92-5 C₂₆H₂₄F₉N₃O₂ 
• 874502-03-1 C₃₀H₃₁F₉N₆O₂ 
• 874501-96-9 C₂₈H₂₆F₉N₇O₂ 
• 874502-50-8 C₂₉H₂₈F₉N₇O₂ 
• 874502-29-1 C₂₈H₂₈ClF₉N₆O₂ 
• 874502-23-5 C₂₈H₂₉F₉N₆O₃ 
• 874502-05-3 C₂₉H₂₉F₉N₆O₄ 
• 874502-32-6 C₂₈H₂₈F₉N₇O₃ 
• 874502-11-1 C₂₉H₃₁F₉N₆O₂ 
• 874502-20-2 C₃₀H₃₃F₉N₆O₂ 
• 874502-14-4 C₃₀H₃₃F₉N₆O₂ 
• 474645-99-3 C₂₄H₂₇F₃N₂O₄ 
• 261947-64-2 ethyl (2R,4S)-4-amino-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate 

Relevant articles and documents

Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors

Cholesteryl Ester Transfer Protein (CETP) is an important therapeutic target for the treatment of atherosclerotic cardiovascular disease. Our molecular modeling study revealed that pentacyclic triterpenoid compounds could mimic the protein-ligand interactions of the endogenous ligand cholesteryl ester (CE) by occupying its binding site. Alignment of the docking conformations of oleanolic acid (OA), ursolic acid (UA) and the crystal conformations of known CETP inhibitor Torcetrapib in the active site proposed the applicability of fragment-based drug design (FBDD) approaches in this study. Accordingly, a series of pentacyclic triterpenoid derivatives have been designed and synthesized as novel CETP inhibitors. The most potent compound 12e (IC50:0.28?μM) validated our strategy for molecular design. Molecular dynamics simulations illustrated that the more stable hydrogen bond interaction of the UA derivative 12e with Ser191 and stronger hydrophobic interactions with Val198, Phe463 than those of OA derivative 12b mainly led to their significantly different CETP inhibitory activity. These novel potent CETP inhibitors based on ursane-type scaffold should deserve further investigation.

Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors

This letter describes the discovery and SAR optimization of tetrazoyl tetrahydroquinoline derivatives as potent CETP inhibitors. Compound 6m exhibited robust HDL-c increase in hCETP/hApoA1 double transgenic model and favorable pharmacokinetic properties.

A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES

The present invention is to provide a process for preparing optically active tetrahydroquinoline derivatives which can be used for the treatment and/or prevention of diseases such as arteriosclerotic diseases, dyslipidemia and the like, and a process for preparing synthetic intermediates thereof. Specifically, (2R,4S)-2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-ylamine or a salt thereof is prepared with fewer steps without using an optical resolution, and the optically active tetrahydroquinoline derivatives are obtained from the amine compound.